Tectonic Therapeutic Q2 net loss widens on higher costs

Tectonic Therapeutic

06/08/2026 21:13

Overview
US biotech firm reported Q2 net loss widened to $22.3 mln from prior year
Company completed enrollment in TX45 APEX Phase 2 trial for PH-HFpEF
Cash and equivalents at $227.1 mln, expected to provide runway into Q1 2029

Outlook
Company expects topline results from TX2100 Phase 1a trial by end of Q3 2026
Tectonic plans to begin TX2100 Phase 2 trial in HHT patients in early 2027
Topline results from TX45 APEX Phase 2 trial expected in early Q1 2027

Result Drivers
R&D SPENDING - Higher research and development expenses driven by contract research, manufacturing costs for TX45 trials, and increased headcount
ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher employee-related costs and non-cash, stock-based compensation

Company press release: ID:nGNX9jbdgz

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$22.29 mln
 
Q2 Income From Operations
 
-$24.22 mln
 
Q2 Loss Per Basic Share
 
$1.18
 
Q2 Operating Expenses
 
$24.22 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Tectonic Therapeutic Inc is $80.00, about 170.6% above its August 5 closing price of $29.56

Reuters Recommended Reads
Aug 6 - vTv Therapeutics Q2 net loss widens on higher trial costs
Aug 4 - Dianthus Therapeutics Q2 net loss widens as R&D costs rise
Aug 5 - Immuneering expects cash runway to fund operations into 2029

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)